Outcome of the Board Meeting held on Wednesday, 12th November, 2025 for consider and approve the unaudited financial result for the half year ended September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts more than Nifty Microcap 250 and 1.9 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Amkay Products Limited announced its H1 FY26 (half year ended September 30, 2025) unaudited financial results. Revenue from operations rose to Rs. 2,301.14 lakhs from Rs. 1,783.82 lakhs in the same period last year, a growth of about 29%. Total revenue stood at Rs. 2,340.45 lakhs versus Rs. 1,856.33 lakhs. Profit after tax grew modestly to Rs. 196.80 lakhs from Rs. 182.53 lakhs, with EPS of Rs. 2.33 versus Rs. 2.24. Operating cash flow turned positive at Rs. 95.48 lakhs compared to a negative Rs. 31.98 lakhs earlier. The statutory auditor issued a Limited Review Report with an unmodified (clean) opinion.
Strong top-line growth signals improving business momentum, but the modest PAT growth suggests margin pressure. The clean auditor opinion and positive operating cash flow support investor confidence, though profit margins may be a point to watch.